Florida Weight Loss MD review

A physical surgical practice offers more than medication

Florida Weight Loss MD is associated with Florida Surgery & Weight Loss Center, a Hollywood, Florida practice naming Sergey Terushkin, MD, FACS. Its broader menu includes sleeve, bypass, revision and balloon procedures alongside medication. That setting may matter to someone who wants a clinician to discuss several approaches rather than a prescription-only storefront. It does not make a surgical price a GLP-1 price: the prominent $9,299 figure concerns a gastric sleeve procedure, not a monthly medication program or an alternative dose tier.

The semaglutide information lists weekly shots from $69, a monthly program from $179 and a three-month supply from $399, with medication, supplies and follow-up described as included. Those are distinct choices and all remain starting amounts. Ask for the intended prescription and complete continuing charge, rather than assume the lowest weekly purchase or divided three-month amount establishes a universal monthly rate. The practice says dosage and pricing can vary after evaluation, so the clinical recommendation and final financial offer need to match.

Week-based packages should keep their real duration

Tirzepatide is advertised from $279 monthly, with $449 for ten weeks and $749 for twenty weeks. The latter packages are labeled two-and-a-half and five months, which overstates their calendar duration. Ten weeks is about 2.3 average calendar months and twenty about 4.6. Compare the full payment and actual weeks rather than divide by the more generous month labels. A package can have a lower equivalent while still committing more money upfront and offering different flexibility from a single-month purchase.

The practice also markets retatrutide through a dedicated page and calculator. Retatrutide is investigational and not FDA-approved; a clinical-looking page or calculator does not establish an approved product or permission to add it to an existing regimen. This is a consequential product-status issue to discuss before deciding whether the service fits. A named surgeon and physical location provide accountability, but they do not change the regulatory status of an unapproved substance or make every marketed treatment appropriate for a particular patient.

Telehealth reach should not be inferred from city pages

The GLP-1 pricing page contains Newark, New Jersey targeting within a Florida practice's site. That is not proof of a Newark clinic or a complete telehealth service-area list. Confirm the actual appointment location, treating practice and eligibility where the patient will be during consultation. The operating company is identified as Florida Comprehensive Health Management LLC at the Hollywood address. Ask which pharmacy dispenses the actual medication and how follow-up occurs for someone who is not attending the physical practice.

Brand options include Wegovy pills and Foundayo, which is orforglipron rather than semaglutide or tirzepatide. Each needs its own product-specific quote. The practice names pregnancy and other clinical exclusions, but that is not the same as a dedicated postpartum or PCOS pathway. Relevant history should be discussed alongside the broader treatment choices. Before buying a package, obtain renewal, cancellation and unused-supply terms. The most useful comparison keeps surgery, starting medication prices, real week durations and the investigational retatrutide concern separate, rather than allowing one impressive-looking number or a physical-clinic setting to resolve them all. A local appointment and remote follow-up can also have different practical requirements to confirm before enrollment.